Quick Answer
Bionano Genomics, Inc. reported Stockholders Equity of $44.42 million for the year ending 2025.
- Bionano Genomics, Inc. showed an increase of +25.6% in Stockholders Equity from 2024 to 2025.
- This data is from Bionano Genomics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$54.02 million | Q2 2018: -$57.28 million | Q3 2018: $15.24 million | Q1 2019: $5.87 million | Q2 2019: -$1.35 million | Q3 2019: -$7.38 million | Q1 2020: -$4.21 million | Q2 2020: $5.84 million | Q3 2020: $14.68 million | Q1 2021: $362.72 million | Q2 2021: $345.87 million | Q3 2021: $341.57 million | Q1 2022: $311.19 million | Q2 2022: $284.73 million | Q3 2022: $281.74 million | Q1 2023: $231.49 million | Q2 2023: $214.76 million | Q3 2023: $119.00 million | Q1 2024: $82.77 million | Q2 2024: $80.34 million | Q3 2024: $48.86 million | Q1 2025: $48.19 million | Q2 2025: $45.37 million | Q3 2025: $49.80 million.
- Over the full 10 years of available data (2016 to 2025), Bionano Genomics, Inc.'s Stockholders Equity has grown by 263.0%.
- Historical annual values: Fiscal year 2025: $44.42 million | Fiscal year 2024: $35.38 million | Fiscal year 2023: $96.16 million | Fiscal year 2022: $249.40 million | Fiscal year 2021: $337.12 million | Fiscal year 2020: $35.08 million | Fiscal year 2019: $3.61 million | Fiscal year 2018: $10.14 million | Fiscal year 2017: -$50.23 million | Fiscal year 2016: -$27.26 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: